Myeloproliferative Disorders Drugs - Global Market Trajectory & Analytics

Global Myeloproliferative Disorders Drugs Market to Reach $9.9 Billion by 2027

Amid the COVID-19 crisis, the global market for Myeloproliferative Disorders Drugs estimated at US$7.8 Billion in the year 2020, is projected to reach a revised size of US$9.9 Billion by 2027, growing at a CAGR of 3.4% over the period 2020-2027. Ph+ Chronic myelogenous leukemia (CML), one of the segments analyzed in the report, is projected to record 3.2% CAGR and reach US$7.3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Ph- Myeloproliferative Neoplasms (MPNs) segment is readjusted to a revised 4.1% CAGR for the next 7-year period.



The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 5.4% CAGR

The Myeloproliferative Disorders Drugs market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 5.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.1% and 2.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Select Competitors (Total 34 Featured):

• Bristol-Myers Squibb
• Inctye
• Novartis
• Pfizer
• Takeda
• Teva